Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Feature|Videos|November 26, 2024
KinetiSol® Technology: Disrupting the Solid Amorphous Dispersion Landscape
Author(s)Austin Px
Elizabeth Hickman (Chief Business Officer, AustinPx) explains the company's approach to improving bioavailability, highlighting KinetiSol technology.
Elizabeth Hickman joined Pharmaceutical Technology to provide an overview of AustinPx, the company's bioavailability offerings, and KinetiSol technology, which represents a major breakthrough in amorphous dispersions. Learn more about:
- How AustinPx was created and the strategy behind taking a technology company and turning it into a CDMO;
- The origin of KinetiSol and how it can provide a faster, broader, and greener technology for amorphous solid dispersions;
- How KinetiSol can alleviate challenges associated with spray drying.
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
5